225 related articles for article (PubMed ID: 20839030)
1. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
Kim GP; Mahoney MR; Szydlo D; Mok TS; Marshke R; Holen K; Picus J; Boyer M; Pitot HC; Rubin J; Philip PA; Nowak A; Wright JJ; Erlichman C
Invest New Drugs; 2012 Feb; 30(1):387-94. PubMed ID: 20839030
[TBL] [Abstract][Full Text] [Related]
2. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib for multiple myeloma.
Popat R; Joel S; Oakervee H; Cavenagh J
Expert Opin Pharmacother; 2006 Jul; 7(10):1337-46. PubMed ID: 16805719
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Li T; Ho L; Piperdi B; Elrafei T; Camacho FJ; Rigas JR; Perez-Soler R; Gucalp R
Lung Cancer; 2010 Apr; 68(1):89-93. PubMed ID: 19524318
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
Rosenberg JE; Halabi S; Sanford BL; Himelstein AL; Atkins JN; Hohl RJ; Millard F; Bajorin DF; Small EJ;
Ann Oncol; 2008 May; 19(5):946-50. PubMed ID: 18272914
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
Shah MA; Power DG; Kindler HL; Holen KD; Kemeny MM; Ilson DH; Tang L; Capanu M; Wright JJ; Kelsen DP
Invest New Drugs; 2011 Dec; 29(6):1475-81. PubMed ID: 20574790
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
Gerecitano J; Portlock C; Moskowitz C; Hamlin P; Straus D; Zelenetz AD; Zhang Z; Dumitrescu O; Sarasohn D; Lin D; Pappanicholaou J; Cortelli BM; Neylon E; Hamelers R; Wright J; O'Connor OA
Br J Haematol; 2009 Sep; 146(6):652-5. PubMed ID: 19624539
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
Barosi G; Gattoni E; Guglielmelli P; Campanelli R; Facchetti F; Fisogni S; Goldberg J; Marchioli R; Hoffman R; Vannucchi AM;
Am J Hematol; 2010 Aug; 85(8):616-9. PubMed ID: 20540156
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
[TBL] [Abstract][Full Text] [Related]
16. A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
Rifkin RM; Greenspan A; Schwerkoske JF; Mandanas RA; Stephenson JJ; Kannarkat GT; Zhan F; Boehm KA; Asmar L; Beveridge R
Invest New Drugs; 2012 Apr; 30(2):714-22. PubMed ID: 20938715
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Ciombor KK; Feng Y; Benson AB; Su Y; Horton L; Short SP; Kauh JS; Staley C; Mulcahy M; Powell M; Amiri KI; Richmond A; Berlin J
Invest New Drugs; 2014 Oct; 32(5):1017-27. PubMed ID: 24890858
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
